Regeneron Pharmaceuticals, Inc. (FRA:RGO)

Market Cap	47.06B
Revenue (ttm)	13.03B
Net Income (ttm)	4.16B
Shares Out	n/a
EPS (ttm)	36.48
PE Ratio	11.30
Forward PE	13.51
Dividend	1.63 (0.36%)
Ex-Dividend Date	May 20, 2025

Volume	n/a
Average Volume	27
Open	448.60
Previous Close	453.20
Day's Range	448.60 - 448.60
52-Week Range	420.00 - 1,088.00
Beta	n/a
RSI	40.49
Earnings Date	Aug 1, 2025

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,106
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RGO

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD